Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Hydrocodone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 7/20 | 0.89 |
| ▸ | OPRD1 known ✓ | P41143 | 6/20 | 0.89 |
| ▸ | OPRK1 known ✓ | P41145 | 4/20 | 0.89 |
| ▸ | LMNA | P02545 | 1/20 | 0.89 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.89 |
| ▸ | MRGPRX2 | Q96LB1 | 1/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrocodone SCHEMBL17523150 | 0.94 | OPRD1 (1.00) | OPRM1OPRD1OPRK1LMNAPDE4D | |
| Hydrocodone SCHEMBL2987 | 0.94 | OPRD1 (1.00) | OPRM1OPRD1OPRK1LMNAPDE4D | |
| Hydrocodone SCHEMBL12638883 | 0.94 | OPRD1 (1.00) | OPRM1OPRD1OPRK1LMNAPDE4D | |
| Hydrocodone SCHEMBL12013631 | 0.94 | OPRD1 (1.00) | OPRM1OPRD1OPRK1LMNAPDE4D | |
| Hydrocodone SCHEMBL12402839 | 0.94 | OPRD1 (1.00) | OPRM1OPRD1OPRK1LMNAPDE4D | |
| Hydrocodone SCHEMBL6744988 | 0.94 | OPRD1 (1.00) | OPRM1OPRD1OPRK1LMNAPDE4D | |
| Hydrocodone SCHEMBL101731 | 0.94 | OPRD1 (1.00) | OPRM1OPRD1OPRK1LMNAPDE4D | |
| Hydrocodone SCHEMBL277572 | 0.94 | OPRD1 (1.00) | OPRM1OPRD1OPRK1LMNAPDE4D | |
| Hydrocodone SCHEMBL21335350 | 0.94 | OPRD1 (1.00) | OPRM1OPRD1OPRK1LMNAPDE4D | |
| Hydrocodone SCHEMBL12369421 | 0.94 | OPRD1 (1.00) | OPRM1OPRD1OPRK1LMNAPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240209403-A1 | METHODS OF PRODUCING MORPHINAN ALKALOIDS AND DERIVATIVES | HERCULES CAPITAL, INC., AS AGENT | 2024-06-27 | — | — | US | disclosed |
| CN-118076344-A | Transmucosal patch comprising cannabinoid and/or opioid | 坎纳医疗制药有限责任公司 | 2024-05-24 | — | — | CN | disclosed |
| US-20240102061-A1 | METHODS OF IMPROVING PRODUCTION OF MORPHINAN ALKALOIDS AND DERIVATIVES | HERCULES CAPITAL, INC., AS AGENT | 2024-03-28 | — | — | US | disclosed |
| US-11884949-B2 | Methods of producing morphinan alkaloids and derivatives | ANTHEIA, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| CN-116964190-A | Method for increasing yields of morphinan alkaloids and derivatives | 安思雅公司 | 2023-10-27 | — | — | CN | disclosed |
| WO-2022109194-A9 | METHODS OF IMPROVING PRODUCTION OF MORPHINAN ALKALOIDS AND DERIVATIVES | ANTHEIA, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| US-20230104286-A1 | METHODS OF PRODUCING NOR-OPIOID AND NAL-OPIOID BENZYLISOQUINOLINE ALKALOIDS | HERCULES CAPITAL, INC., AS AGENT | 2023-04-06 | — | — | US | disclosed |
| US-11427827-B2 | Engineered benzylisoquinoline alkaloid epimerases and methods of producing benzylisoquinoline alkaloids | ANTHEIA, INC. (US) | 2022-08-30 | — | — | US | disclosed |
| US-20220162656-A1 | METHODS OF IMPROVING PRODUCTION OF MORPHINAN ALKALOIDS AND DERIVATIVES | HERCULES CAPITAL, INC., AS AGENT | 2022-05-26 | — | — | US | disclosed |
| EP-3608322-B1 | SYRINGE CONTAINING NMTX BROMIDE | WYETH LLC (US) | 2022-04-20 | — | — | EP | disclosed |
| US-10544420-B2 | Engineered benzylisoquinoline alkaloid epimerases and methods of producing benzylisoquinoline alkaloids | ANTHEIA, INC. (US) | 2020-01-28 | — | — | US | disclosed |
| US-20190144900-A1 | METHODS OF PRODUCING NOR-OPIOID AND NAL-OPIOID BENZYLISOQUINOLINE ALKALOIDS | HERCULES CAPITAL, INC., AS AGENT | 2019-05-16 | — | — | US | disclosed |
| US-20190078100-A1 | ENGINEERED BENZYLISOQUINOLINE ALKALOID EPIMERASES AND METHODS OF PRODUCING BENZYLISOQUINOLINE ALKALOIDS | HERCULES CAPITAL, INC., AS AGENT | 2019-03-14 | — | — | US | disclosed |
| WO-2019028390-A1 | ENGINEERED BENZYLISOQUINOLINE ALKALOID EPIMERASES AND METHODS OF PRODUCING BENZYLISOQUINOLINE ALKALOIDS | ANTHEIA, INC. (US) | 2019-02-07 | — | — | WO | disclosed |
| EP-2675893-A1 | DIRECTED DIFFERENTIATION OF OLIGODENDROCYTE PRECURSOR CELLS TO A MYELINATING CELL FATE | The Scripps Research Institute (US) | 2013-12-25 | — | — | EP | disclosed |
| US-20130150377-A1 | Tetrahydropyridinyl and Dihydropyrrolyl Compounds and the Use Thereof | SHIONOGI & CO., LTD. (JP) | 2013-06-13 | — | — | US | disclosed |
| WO-2012112933-A1 | DIRECTED DIFFERENTIATION OF OLIGODENDROCYTE PRECURSOR CELLS TO A MYELINATING CELL FATE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2012-08-23 | — | — | WO | disclosed |
| EP-2484346-A1 | Pharmaceutical compositions | Alpharma Pharmaceuticals, LLC (US) | 2012-08-08 | — | — | EP | disclosed |
| US-8067243-B2 | Methods and systems for analyzing medication levels in a sample | OREGON MEDICAL LABORATORIES (US) | 2011-11-29 | — | — | US | disclosed |
| US-20100051801-A1 | METHODS AND SYSTEMS FOR ANALYZING MEDICATION LEVELS IN A SAMPLE | OREGON MEDICAL LABORATORIES | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150377-A1 | Tetrahydropyridinyl and Dihydropyrrolyl Compounds and the Use Thereof | TRPV1, CACNA1A, CACNA1E | OPRM1 79/4885OPRD1 55/4885OPRK1 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.